In the current study, we sought to assess the possibility of using MSCs followed by G-CSF mobilization intravenous infusion as a therapeutic modality in patients with end-stage liver diseases in comparison to our previous studies using CD133 and CD34 intrahepatic infusion. Here, PROM1 is linked to End Stage Liver Disease.